# A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）

> **NCT07399444** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 38 (estimated)

## Conditions studied

- Multiple Myeloma (MM)

## Interventions

- **BIOLOGICAL:** LVIVO-TaVec400 product

## Key facts

- **NCT ID:** NCT07399444
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-10
- **Primary completion:** 2028-07-10
- **Final completion:** 2030-05-10
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-02-10

## Collaborators

- Nanjing Legend Biotech Co.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07399444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07399444, "A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07399444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*